Intrexon Corp (NYSE:XON) Major Shareholder Randal J. Kirk Sells 95,241 Shares

Intrexon Corp (NYSE:XON) major shareholder Randal J. Kirk sold 95,241 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $0.65, for a total transaction of $61,906.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

NYSE:XON traded up $0.11 during mid-day trading on Friday, reaching $4.50. 1,514,925 shares of the company were exchanged, compared to its average volume of 2,457,732. Intrexon Corp has a 12 month low of $3.95 and a 12 month high of $19.94.

Intrexon (NYSE:XON) last issued its quarterly earnings data on Thursday, February 28th. The biotechnology company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.14. The company had revenue of $43.19 million for the quarter, compared to the consensus estimate of $61.81 million.

A number of large investors have recently modified their holdings of the business. Macquarie Group Ltd. lifted its position in Intrexon by 3.2% during the 4th quarter. Macquarie Group Ltd. now owns 55,427 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 1,743 shares during the period. Cambridge Investment Research Advisors Inc. lifted its position in Intrexon by 4.2% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,823 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 1,835 shares during the period. Legal & General Group Plc lifted its position in Intrexon by 10.2% during the 4th quarter. Legal & General Group Plc now owns 29,368 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 2,709 shares during the period. Raymond James & Associates lifted its position in Intrexon by 11.0% during the 4th quarter. Raymond James & Associates now owns 28,634 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 2,834 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in Intrexon by 1.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 161,385 shares of the biotechnology company’s stock valued at $1,055,000 after purchasing an additional 2,882 shares during the period. 84.92% of the stock is currently owned by hedge funds and other institutional investors.

XON has been the topic of several analyst reports. JMP Securities reaffirmed a “buy” rating and issued a $43.00 target price on shares of Intrexon in a report on Wednesday, March 6th. Zacks Investment Research raised shares of Intrexon from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a report on Saturday, January 19th. Finally, Northland Securities lowered shares of Intrexon from an “outperform” rating to a “market perform” rating in a report on Friday, March 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $34.00.

COPYRIGHT VIOLATION WARNING: This news story was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/04/26/intrexon-corp-xon-major-shareholder-randal-j-kirk-sells-95241-shares.html.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Read More: Net Income

Insider Buying and Selling by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.